MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Flagship Pioneering partners with CUHP and MTI to advance research, clinical translation, and talent development in the UK. The collaboration gives Flagship’s companies access to Cambridge’s resources ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Quotient Therapeutics, a biotech company founded in 2022, hopes to take this transatlantic model and commercialise it. Its main research lab is in Great Chesterford, a village just outside Cambridge, ...

A temporary freeze on meetings on the National Institutes of Health could lead to delays in disbursing research grants and in approving crucial clinical trials.

Thermo Fisher Scientific should be safe. RFK Jr. may disrupt Big Pharma, but he’s unlikely to cause research to completely ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...

Following his speech, Trump signed a slew of executive orders—declaring a national emergency at the southern border and an end to birthright citizenship, as well as ending use of the CBP1 app, among ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 12,155 calls trading, 1.0x expected, and implied vol increasing almost 2 ...